Cannabix Technologies Inc. (formerly West Point Resources Inc.) (CSE: BLO, US OTC: BLOZF, Frankfurt: 8CT:FRA) is a Vancouver, B.C. based technology company.o
Cannabix Technologies has the exclusive North American license for the Cannabix Marijuana Breathalyzer from Cannabix Breathalyzer Inc.
Cannabix Technologies has Rights to "Partial ovoidal FAIMS electrode - Patent 8,237,118" from the University of Florida
for the WORLD for CONTROLLED SUBSTANCE
What is FAIMS-MS?
40 Minute Video with Dr Yost https://www.msacl.org/index.php?header=Learning_Center&tab=Video_Management&subtab=Video_Request&id=8&conference=2015_US&type=plenary Cannabix Technologies' common shares trade on the Canadian Securities Exchange and US OTC Pinksheets and European Frankfurt Exchange. Cannabix Technologies Inc. is the developer of the patent pending Cannabix Marijuana Breathalyzer for law enforcement and the workplace. The Cannabix Marijuana Breathalyzer drug-impairment recognition system is based on breath testing technology that has been developed to test individuals for recent consumption of the THC component of marijuana. Cannabix is advancing its products to enable law enforcement personnel to use this technology to enhance detection of marijuana impaired driving offences on North American roads at a time when marijuana is becoming legal in many jurisdictions. Cannabix is working to develop a drug-testing device that will detect Tetrahydrocannabinol (THC- the psychoactive component of marijuana that causes intoxication) using breath samples. The device would be used to provide detection of THC at the roadside to identify drivers intoxicated by the use of marijuana. The device will also be useful for other practical applications such as testing employees in the workplace where intoxication by THC can be hazardous.
The device is currently in BETA 1.0 development and the Company is rapidly developing this technology for BETA 2.0 for Third Party Testing
http://www.cannabixtechnologies.com/ CSE:BLO Pinksheets: BLOZF Frankfurt: 8CT:FRA
Issued and Outstanding 77,862,442(as of Septmber 5, 2016)
Warrants Issued but not Exerscised 13,914,159
Options Issued but not Exercised 6,661,000
IF a Patent is Issued another 5M Shares
Fully Diluted w/Warrants, w/Options and w/Patent issued 103,437,601 Cannabix Corporate Video https://www.youtube.com/watch?v=ix3Uss9zrBo
Kal Malhi, President and Director Kal Malhi, President, Director Mr. Malhi is a Vancouver based entrepreneur and the founder of Cannabix Breathalyzer Inc. Mr. Malhi is a retired member of the Royal Canadian Mounted Police and is also President of BullRun Group, a private investment company specializing in early stage business development. Mr Malhi brings a wealth of business and law enforcement experience to the management team and is cognizant of the issues of protecting individuals’ rights to privacy while maximizing public safety through law enforcement initiatives. Dr. Raj Attariwala, MD, PhD., Lead Engineer Dr. Attariwala is a Vancouver based dual board certified Radiologist and Nuclear Medicine physician certified in both Canada and the United States. He received his formal medical training at University of British Columbia with periods of specialized medical training at Memorial Sloan Kettering Cancer Centre (New York), UCLA and USC. He holds a doctorate in Biomedical Engineering from Northwestern University (Evanston, IL). Dr. Attariwala is a practicing physician in British Columbia and is the owner of AIM medical imaging in Vancouver. He has pioneered advances in the field of whole body medical imaging thru his work and authored numerous publications and presented at international medical conferences on whole body imaging and cancer detection. Dr Attariwala has worked closely with the breath testing technology developed by the Karolinska Institute and Dr Olof Beck and utilized his educational training and background in Biomedical Engineering to formulate product design and patent applications for Cannabix Breathalyzer products. Dr. Attariwala also has several other medical device patents under developments in the field of Nuclear Medicine. Dr. Bruce Goldberger, PhD, Senior Advisor Dr. Goldberger is a professor, and the director of toxicology for the Department of Pathology, Immunology and Laboratory Medicine in the College of Medicine at the University of Florida. Dr. Goldberger is the editor-in-chief of the Journal of Analytical Toxicology; the president of the American Board of Forensic.
Richard A. Yost Ph.D., Scientific Advisor
Dr. Yost, Col. Allen R. & Margaret G. Crow Professor and Head of Analytical Chemistry at the University of Florida received his B.S. degree in Chemistry from the University of Arizona in 1974. In 1975 he pursued an NSF graduate fellowship at Michigan State University focusing on electronics and computerized instrumentation. He received his Ph.D. in 1979 and assumed the position of Assistant Professor at the University of Florida and went on to become head of the Analytical Chemistry Division. Jared Boock Ph.D, Principal investigator
Worked on a high-field asymmetric waveform ion mobility spectrometry (FAIMS) - based
method of detection for transition metals. Conducted characterization of the types of ions that form
during the electrospray ionization (ESI) process for over 25 metal salts. Invented an atmospheric
pressure ion guide (patent pending). Taught four semesters of analytical chemistry laboratory; recipient of the Department of Chemistry Teaching Award for 2015. Rocco Iannapollo, Advisor
Mr. Iannapollo is an expert on substance abuse programs with more than 20 years of experience in the oil and gas industry, working for fortune 50 companies. Rocco has extensive experience with supplier, employer, and DOT compliance policies and strategies. He also brings deep business acumen regarding operations and supply chain best practices. Mr. Iannapollo is a member of the Substance Abuse Program Administrator’s Association (SAPAA), the Drug and Alcohol Testing Industry Association (DATIA), as well as a speaker and regular contributor to the International Forum for Drug and Alcohol Testing (IFDAT). Rav Mlait, MBA – CEO, Director
.Mr. Mlait has extensive experience in managing and raising capital for public and private companies. Mr. Mlait holds an MBA from Royal Roads University in British Columbia with a specialization in Executive Management and his BA (Economics) from Simon Fraser University and has worked with public companies listed on the TSX and TSX Venture exchange. Mr. Mlait was VP of Corporate development for knowledge-management and CRM software developer, Knexa Solutions Ltd., and financial web portal, Stockhouse Media Corporation. Bryan Loree BA, CMA –CFO, Director Mr. Loree has held various senior accounting roles for public and private companies in various industries including, renewable energy, exploration, and construction. During this time he has also performed capital raising activities for both private and public companies, primarily in the exploration and renewable energy sectors. Prior to entering the accounting field, Mr. Loree spent three years as an investor relations manager for public exploration companies and two years in the banking industry. Mr. Loree holds a Certified Management Accountant designation, a Financial Management Diploma from the British Columbia Institute of Technology, and a BA from Simon Fraser University. Thomas Clarke, M,Sc, Director Mr. Clarke served as a geologist for TSX Venture listed, BonTerra Resources from May 2010 to October, 2012. During his tenure, BonTerra defined an initial NI 43-101 compliant resource under his leadership. Thomas is a geologist holding a BSc. (Honours) and MSc in Geology from the University of the Witwatersrand as well as a BSc in Geography from the University of Lethbridge.
Andrew Davies, Advisor
Mr. Davies is a cannabinoid expert who has over 25 years of experience in the pharmaceutical industry and was instrumental in securing the first US IND for synthetic Cannabidiol (CBD) at Yale University. Andrew is a Chartered Mechanical Engineer and holds a BEng from the University of Liverpool and an International Executive MBA from the University of Middlesex Business School, London. Andrew is the CEO of STI Pharmaceuticals Ltd., a leading cannabinoid research company based in London, England. He is also a sought after speaker at cannabinoid conferences globally. Dr. (h.c.) Marilyn Huestis, PhD, Scientific Advisor Dr. Huestis is one of the world’s foremost experts on the effects of marijuana use on driving impairment. Dr. Huestis is a sought after international speaker, scholar and scientist. Dr. Huestis was a tenured Senior Investigator and Chief of Chemistry and Drug Metabolism at National Institute for Drug Abuse (NIDA’s) Intramural Research Program (IRP) in Baltimore, Maryland and a Professor at the University of Maryland School of Medicine (retired in 2016). Dr. Huestis received her Bachelor’s degree (cum laude) in Biochemistry from Mount Holyoke College, a Master's in Clinical Chemistry with honors from the University of New Mexico, and a Ph.D. in Toxicology with honors from the University of Maryland School of Medicine.